IL280859A - Use of gboxdol for the treatment of gastrointestinal disorders and asthma - Google Patents

Use of gboxdol for the treatment of gastrointestinal disorders and asthma

Info

Publication number
IL280859A
IL280859A IL280859A IL28085921A IL280859A IL 280859 A IL280859 A IL 280859A IL 280859 A IL280859 A IL 280859A IL 28085921 A IL28085921 A IL 28085921A IL 280859 A IL280859 A IL 280859A
Authority
IL
Israel
Prior art keywords
gaboxadol
asthma
treatment
gastrointestinal tract
tract disorders
Prior art date
Application number
IL280859A
Other languages
English (en)
Hebrew (he)
Original Assignee
Ovid Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ovid Therapeutics Inc filed Critical Ovid Therapeutics Inc
Publication of IL280859A publication Critical patent/IL280859A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • A61K31/41521,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL280859A 2018-08-22 2021-02-14 Use of gboxdol for the treatment of gastrointestinal disorders and asthma IL280859A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862721013P 2018-08-22 2018-08-22
PCT/US2019/047673 WO2020041574A1 (en) 2018-08-22 2019-08-22 Use of gaboxadol in the treatment of gastrointestinal tract disorders and asthma

Publications (1)

Publication Number Publication Date
IL280859A true IL280859A (en) 2021-04-29

Family

ID=69591079

Family Applications (1)

Application Number Title Priority Date Filing Date
IL280859A IL280859A (en) 2018-08-22 2021-02-14 Use of gboxdol for the treatment of gastrointestinal disorders and asthma

Country Status (10)

Country Link
US (1) US20210177805A1 (https=)
EP (1) EP3823619A4 (https=)
JP (1) JP2021535106A (https=)
KR (1) KR20210049855A (https=)
CN (1) CN112888437A (https=)
AU (1) AU2019326539A1 (https=)
CA (1) CA3110218A1 (https=)
IL (1) IL280859A (https=)
MX (1) MX2021002113A (https=)
WO (1) WO2020041574A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230107927A1 (en) 2020-02-28 2023-04-06 First Wave Bio, Inc. Methods of treating iatrogenic autoimmune colitis
KR20220157426A (ko) * 2020-03-25 2022-11-29 세이지 테라퓨틱스, 인크. 호흡기 병태의 치료를 위한 작용제의 용도

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0974351A3 (en) * 1998-04-24 2000-12-13 Jouveinal Medicament for preventing and treating gastrointestinal damage
AU4307800A (en) * 1999-04-30 2000-11-17 Merab Lomia New indication for use of antiepileptic agents and medicines
WO2006102093A1 (en) * 2005-03-18 2006-09-28 Transform Pharmaceuticals, Inc. Gaboxadol forms, compositions thereof, and related methods
US20070203216A1 (en) * 2006-02-14 2007-08-30 Bjarke Ebert Method of treating inflammatory diseases
IL256912B2 (en) * 2015-07-17 2024-01-01 Ovid Therapeutics Inc Methods of treating developmental disorders with gaboxadol

Also Published As

Publication number Publication date
WO2020041574A1 (en) 2020-02-27
JP2021535106A (ja) 2021-12-16
AU2019326539A1 (en) 2021-03-11
KR20210049855A (ko) 2021-05-06
CN112888437A (zh) 2021-06-01
US20210177805A1 (en) 2021-06-17
EP3823619A1 (en) 2021-05-26
MX2021002113A (es) 2021-06-23
CA3110218A1 (en) 2020-02-27
EP3823619A4 (en) 2021-11-17

Similar Documents

Publication Publication Date Title
IL281445A (en) Therapeutic nanoparticles and methods for their use
IL271117B (en) Diazabicyclic mutated imidazopyrimidines and their use in the treatment of respiratory disorders
IL275678A (en) Using nitrous oxide and inhaled oxygen to treat pulmonary hypertension
PL4014976T3 (pl) Aprocitentan do stosowania w leczeniu nadciśnienia tętniczego i chorób z nim związanych w połączeniu z walsartanem
ZA201807098B (en) Cannabionid and cannabis-based compositions and methods for the treatment of inflammatory conditions of the gastrointestinal tract
IL261932A (en) Use of probiotics in the treatment and/or prevention of eczema
IL271072A (en) Devices and methods for the treatment of body surface disorders
IL268210A (en) Use of gaboxadol in the treatment of tinnitus
IL272414A (en) Use of gaboksadol in the treatment of diabetes and related conditions
IL272962A (en) Use of gaboksadol for the treatment of anesthesia
IL260987A (en) Treatment and diagnosis of inflammatory disorders
IL280859A (en) Use of gboxdol for the treatment of gastrointestinal disorders and asthma
IL277805A (en) Use of gaboksadol in the treatment of substance use disorders
GB201700692D0 (en) Novel compounds and their use in the treatment of schistosomiasis
ZA201903828B (en) Novel glutaminyl cyclase inhibitors and the use thereof in treatment of various diseases
PL3541185T3 (pl) Zastosowanie 2-hydroksybenzyloaminy w leczeniu i zapobieganiu nadciśnieniu płucnemu
HUE063383T2 (hu) Folyékony készítmény az oro-faringo-laringo-özofageális traktus nyálkahártyájának kezelésében történõ felhasználásra
IL284689A (en) Endoscopic device and methods of its use
GB2574747B (en) Use of lambda interferons in the treatment of obesity-related disorders and related diseases
IL284032A (en) 3 beta-(benzyloxy)-17 alpha-methyl-paragan-5-en-20-one for use in the treatment of cognitive disorders
IL276792A (en) Inhaler and methods for using it
PT3937949T (pt) Fitoecdisonas e seus derivados para utilização no tratamento da alteração da função respiratória
HK40053115A (en) Use of gaboxadol in the treatment of gastrointestinal tract disorders and asthma
AU2019901175A0 (en) Compositions and methods of treatment of conditions of the gastrointestinal tract
CA3253199A1 (en) Devices and methods for the treatment of body surface disorders